Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension.

Fremanezumab is a treatment approved for migraine prevention in many countries. This study focused on its effects in Chinese adults with migraines. Researchers conducted a Phase 3 trial with three groups. One group received monthly fremanezumab, another received it quarterly, and a third group got a placebo. The trial included a 4-week screening and a 12-week treatment period. After the initial phase, all participants received monthly fremanezumab. The main goal was to see how much monthly migraine days decreased. Secondary goals looked at changes in migraine days during the first month of treatment. Results showed that fremanezumab significantly reduced the number of migraine days. This indicates that fremanezumab is effective for migraine prevention in the Chinese population. Overall, the study suggests that this treatment could help many people suffering from migraines in China. Clinical relevance: This research shows that fremanezumab is effective for migraine prevention in Chinese adults, potentially improving treatment options for this population.